Parent-son-provider Decision-making About HPV Vaccination
An Investigation of Parent-son-provider Decision-making About HPV Vaccination
The objectives of this study are:
- To better understand factors associated with acceptance and refusal of HPV vaccine among parent-son pairs and the process of parent-son decision-making with respect to vaccination.
- To evaluate health care providers (HCPs) attitudes, implementation intentions, and planned communication strategies with respect to HPV vaccination of adolescent boys.
Hypothesis 1: Sons will have a significant role in the process of parent-son decision-making about HPV vaccination. The relative importance of this role will increase with the son's age.
Hypothesis 2: Pediatric HCPs will be unsure about vaccinating males and will lack knowledge about issues related to male HPV infection and vaccination.
Přehled studie
Postavení
Podmínky
Detailní popis
This protocol will involve individual semi-structured qualitative interviews with 30 parent-son dyads and 20 pediatric health care providers. Parent-son pairs will be recruited from IUMG primary care adolescent health clinics. Recruitment will occur and consent/assent for participation obtained during the visit with the health care provider, with the physician out of the room. Interviews with parents and sons will take place after the health care appointment and after HPV vaccine acceptance/refusal. Parents and sons will be administered a brief questionnaire that will cover socio-demographic and other background information. The parent-son interviews will be separate, simultaneous one-on-one ethnographic interviews (30-60 min) that focus on the decision making process regarding HPV vaccination (yes/no). Each interview will consist of 8-10 open-ended questions, serving as an elicitation device. Sample questions include: (1) Tell me what you understand about the HPV vaccine? (2) Tell me what happened when you were in the examination room and your doctor asked you and your parent/son about getting the vaccine? (3) Was the decision made quickly, or did you have a conversation about it first? (4) Who had the most influence on the decision, you or your parent/son? (5) Why did you decide to get (or not to get) the vaccine? The interviewer will ask participants to elaborate on the meaning and contexts of their responses, and look for organization in what the participant is saying, developing and testing hypotheses during the interview. Each interview will be conducted by a trained, gender-matched research assistant.
Health care providers will be interviewed at a different time, and the interviews (25-30 min) will focus on HPV vaccine related attitudes, supply, costs, communication and perceived benefits associated with vaccinating adolescent males, rather than care to specific patients. Sample questions include: (1) How do you inform patients about the HPV vaccine? (2) What is the specific wording that you use when you offer HPV vaccine? Be very specific. Don't leave out any detail.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- IU Medical Group Primary Care Clinic (IUMG-PC), including Wishard primary care clinics
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
Adolescent:
- English-speaking adolescent boys
- 13-17 years of age
- No prior receipt of HPV vaccine
- Accompanied by parent
Parent:
- English-speaking or Spanish-speaking parent
Health Care Provider:
- Physician
- Provides care to adolescent boys 13-17 years of age
Exclusion Criteria:
Adolescent:
- Non-English-speaking
- Younger than 13 or older than 17
- Previous receipt of 1 or more doses of HPV vaccine
Parent:
- Non-English-speaking and Non-Spanish-speaking
Health Care Provider:
- Not a physician
- Does not provide care to males 13-17 years of age
Studijní plán
Jak je studie koncipována?
Kohorty a intervence
Skupina / kohorta |
|---|
|
Male Adolescents
Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
|
|
Parents of Male Adolescents
Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
|
|
Health Care Providers for Males 13-17 yo
Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Decision Regarding Acceptance/Refusal of 1st Dose of HPV Vaccine
Časové okno: Up to 1 hour
|
The semi-structured interviews with parents & sons will focus on how the decision was made to accept or refuse HPV vaccine.
The interviews will take place immediately after the clinic visit during which the vaccination decision was made.
|
Up to 1 hour
|
|
Health care providers decision-making regarding HPV vaccination of males
Časové okno: Up to 1 hour
|
Semi-structured interviews will be conducted with 20 health care providers regarding their decision-making around vaccinating adolescent male patients against HPV
|
Up to 1 hour
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- Merck IISP 38094
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Očkování proti lidskému papilomaviru
-
Jinling Hospital, ChinaNeznámýCrohnova nemoc | Methylace | Illumina Human Methylation 850k BeadChipČína
-
Merck Sharp & Dohme LLCDokončenoUroteliální karcinom Associated 1 RNA, Human
-
Ufuk UniversityNáborStav imunizace proti HPV | HPV (Human Papillomavirus) - asociovanýTurecko (Türkiye)
-
KTO Karatay UniversityNáborHPV (Human Papillomavirus) - asociovanýTurecko (Türkiye)
-
Paul W. Read, MDUkončenoOrofaryngeální spinocelulární karcinom (OPSCCA) | HPV (Human Papillomavirus) - asociovanýSpojené státy
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of Hangzhou; Women's Hospital School Of Medicine Zhejiang... a další spolupracovníciZatím nenabírámeFotodynamická terapie (PDT) | HPV (Human Papillomavirus) - asociovaný | CIN 2 | Hsil, vysoce kvalitní spinocelus intraepiteliální lézeČína
-
M.D. Anderson Cancer CenterZatím nenabírámeHPV (Human Papillomavirus) - asociovanýSpojené státy
-
Vastra Gotaland RegionNáborMyelodysplastický syndrom | Akutní myeloidní leukémie | Difuzní velký B buněčný lymfom (DLBCL) | HPV (Human Papillomavirus) - asociovaný | Příjemci transplantace alogenních kmenových buněkŠvédsko
-
QurasenseNáborScreening rakoviny děložního čípku | HPV infekce | HPV | HPV infekce | Screeningový test | HPV DNA | Infekce HPV 16 | HPV (Human Papillomavirus) - asociovaný | Rakovina děložního čípku Cin Grade | Vysoce rizikové HPV | Rakovina děložního čípku (Včasná detekce)Spojené státy
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbDokončenoStádium IVA spinocelulárního karcinomu ústní dutiny | Stádium IV hypofaryngeálního spinocelulárního karcinomu | Stádium IVA laryngeálního spinocelulárního karcinomu | Fáze IVA orofaryngeálního spinocelulárního karcinomu | Stádium IVB Laryngeální spinocelulární karcinom | Stádium IVB orofaryngeální... a další podmínkySpojené státy